Drug Trial Radar · NCT06553339
A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors
Last checked: Nov 19, 2026Latest source record: Aug 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Jul 19, 2024
Primary completion
Jul 31, 2026
Study completion Jul 31, 2028
Sponsor
- Lead sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 14, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of the Phase Ia portion is to identify the maximum tolerated dose or maximum acceptable dose MTD/MAD of HS-10516. The phase Ib portion will evaluate the preliminary efficacy of HS-10516 in patients with VHL Syndrome Associated Tumors.
Conditions
- Von Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma
Interventions
Oral HS-10516Drug
Oral HIF-2α inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ia: MTD/MAD of HS-10516Time frame: Approximately 2 months
- Phase Ib: Objective Response Rate (ORR) by Independent Review Committee (IRC)Time frame: Approximately 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.